abstract |
The present disclosure relates to an anti-TRBC1 antigen binding domain characterized by a variable chain sequence. The variable chain CDR sequences are (VH CDR1) GYTFT, (VH CDR2) NPYNDDIQS, (VH CDR3) GAGYNFDGAYRFFDF, and (VL CDR1) RSSQRLVHSNGNTYL, (VL CDR2) RVSNRFP, (VLCDR2) RVSNRFP. The claimed humanized antibody is derived from the mouse JOV1I antibody. Use in cancer treatment. |